Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi

Clin Mol Hepatol. 2023;29(2):242-251. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0102

View: 4085 Download: 208 Web of Science: 3 Crossref: 4

Takuji Torimura, Hideki Iwamoto

Clin Mol Hepatol. 2021;27(2):236-245. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0204

View: 8134 Download: 374 Web of Science: 40 Crossref: 38

Sung Eun Kim, Han Chu Lee, Kang Mo Kim, Young-Suk Lim, Young-Hwa Chung, Yung Sang Lee, Dong Jin Suh

Clin Mol Hepatol. 2011;17(2):113-119. Published online June 23, 2011

DOI: https://doi.org/10.3350/kjhep.2011.17.2.113

View: 8428 Download: 48 Crossref: 25

1 |

Viewed By 5399	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5363	MAFLD: How is it different from NAFLD?
Viewed By 5247	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3927	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3904	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 68	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

Search